

AMENDMENT AND RESPONSE TO OFFICE ACTION  
U.S.S.N. 10/526,120

**Claims Listing**

Claims 1 to 15. (Cancelled)

16. (Currently amended) A method for immunization against an allergen comprising administering to a subject in a first phase a recombinant nucleic acid ~~according to any one of claims 1 to 13~~ comprising a gene encoding a first signal peptide operably linked to a gene encoding the allergen wherein the first signal peptide mediates the translocation of the allergen into the endoplasmic reticulum, and in a second phase administering the allergen to the subject.

17. (Original) The method of claims 16 wherein the allergen is administered in combination with an adjuvant.

18. (Previously presented) The method of claim 16 wherein the nucleic acid is administered in the first phase over a period of time sufficient to induce long term immune memory in the subject.

19. (Original) The method of claim 18 wherein multiple doses of the nucleic acid is administered in the first phase over a period of about a year.

20. (Previously presented) The method of claim 16 comprising administering the allergen to the subject intraperitoneally and subsequently by aerosol.

Claims 21-22. (Cancelled)

23. (Previously presented) The method of claim 16 wherein the nucleic acid is administered by intramuscular or intradermal injection.

AMENDMENT AND RESPONSE TO OFFICE ACTION  
U.S.S.N. 10/526,120

24. (Original) A method for immunization against an allergen comprising administering to a subject a nucleic acid comprising an expressible allergen gene in a first phase over a period of about a year so as to induce long term immune memory in the subject; and administering the allergen to the subject in a second phase.

25. (Currently amended) A method for treating or preventing an allergic reaction in a subject comprising administering a recombinant nucleic acid according to any one of claims 1 to 13 to the subject, wherein the recombinant nucleic acid comprises a gene encoding a first signal peptide operably linked to a gene encoding an allergen wherein the first signal peptide mediates the translocation of the allergen into the endoplasmic reticulum.

26. (Previously presented) The method of claim 25 wherein the recombinant nucleic acid is administered orally or by intramuscular or intradermal injection.

27. (Previously presented) The method of claim 25 wherein the allergic reaction is asthma or rhinitis.

Claims 28- 32. (Cancelled)